Tetradecanoylphorbol acetate - Biosuccess Biotech/Rich Pharmaceuticals

Drug Profile

Tetradecanoylphorbol acetate - Biosuccess Biotech/Rich Pharmaceuticals

Alternative Names: PD-616; Phorbol 12-myristate 13-acetate; Phorbol myristate acetate; PMA; RP 323; TPA

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rutgers; Zhengzhou University
  • Developer Biosuccess Biotech; Rich Pharmaceuticals; Rutgers
  • Class Antineoplastics; Antiretrovirals; Esters; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitogen-activated protein kinase modulators; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Stroke
  • No development reported HIV infections

Most Recent Events

  • 08 Jun 2017 Rich Pharmaceuticals filed submission package to an Institutional Review Board in Thailand
  • 31 May 2017 Rich Pharmaceuticals announces intention to file submission package to the Thailand Food and Drug Administration for a phase I/II trial in Acute myeloid leukaemia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top